In this data-drenched discussion, UCSF specialists review how CAR T-cells are being used in hematologic malignancies, including aggressive lymphoma and difficult-to-treat myeloma, as well as for solid tumors, and reveal what's on the horizon with regard to these products. They discuss current options, including response rates; factors that put patients at risk for failure; and how challenges – such as transience and toxicity – may be overcome. They also look at problems with patient access that inform decision-making, including the timing of referral.
Professor and Chief, Division of Hematology and Oncology
Professor and Chief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, UCSF
Wong is a member of the American Society of Hematology and American Society of Clinical Oncology.